IT8448873A0 - Composizione per rivestimento enterico di compresse farmaceutiche esimili - Google Patents

Composizione per rivestimento enterico di compresse farmaceutiche esimili

Info

Publication number
IT8448873A0
IT8448873A0 IT8448873A IT4887384A IT8448873A0 IT 8448873 A0 IT8448873 A0 IT 8448873A0 IT 8448873 A IT8448873 A IT 8448873A IT 4887384 A IT4887384 A IT 4887384A IT 8448873 A0 IT8448873 A0 IT 8448873A0
Authority
IT
Italy
Prior art keywords
composition
enteric coating
similar pharmaceutical
pharmaceutical tablets
tablets
Prior art date
Application number
IT8448873A
Other languages
English (en)
Italian (it)
Inventor
Stuart C Porter
Edward J Grillo Susan Woznicki
Andrea Louis F D
Original Assignee
Colorcon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorcon filed Critical Colorcon
Publication of IT8448873A0 publication Critical patent/IT8448873A0/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
IT8448873A 1983-09-19 1984-09-18 Composizione per rivestimento enterico di compresse farmaceutiche esimili IT8448873A0 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/533,541 US4556552A (en) 1983-09-19 1983-09-19 Enteric film-coating compositions

Publications (1)

Publication Number Publication Date
IT8448873A0 true IT8448873A0 (it) 1984-09-18

Family

ID=24126414

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8448873A IT8448873A0 (it) 1983-09-19 1984-09-18 Composizione per rivestimento enterico di compresse farmaceutiche esimili

Country Status (8)

Country Link
US (1) US4556552A (enExample)
EP (1) EP0156852A1 (enExample)
JP (1) JPS60502207A (enExample)
KR (1) KR850700009A (enExample)
AU (1) AU3397184A (enExample)
IT (1) IT8448873A0 (enExample)
PH (1) PH21092A (enExample)
WO (1) WO1985001207A1 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971791A (en) * 1985-08-26 1990-11-20 The Procter & Gamble Company Taste masking compositions
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
DK0594607T3 (da) 1990-03-02 1998-04-14 Autoimmune Inc Forøgelse af nedreguleringen af autoimmune sygdomme ved oral eller enteral indgivelse af autoantigener
FR2660317B1 (fr) * 1990-03-27 1994-01-14 Seppic Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US6224911B1 (en) * 1993-03-16 2001-05-01 Syntex (U.S.A.) Llc Process for the preparation of enteric coated pharmaceutical dosage forms
US5436011A (en) * 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
US5800831A (en) * 1993-07-28 1998-09-01 Pfizer Inc. Psoriasis treatment with polymer film
US6113893A (en) * 1993-07-28 2000-09-05 Pfizer Inc. Psoriasis treatment
JPH09501947A (ja) * 1993-08-30 1997-02-25 ワーナー−ランバート・コンパニー 改良された錠剤コーティング方法
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JP2001514884A (ja) 1997-08-19 2001-09-18 ハイブリドン・インク 新規なｈｉｖ特異的合成オリゴヌクレオチド及びその使用方法
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
DE60129552T2 (de) 2000-05-24 2008-04-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services E-selectin zur behandlung oder vorbeugung von schlaganfall
EP1381376B1 (en) 2000-11-20 2008-01-02 Sorbent Therapeutics, Inc. Water-absorbent polymers and their use
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
EP1339395A2 (en) 2000-11-28 2003-09-03 Fmc Corporation Edible pga (propylene glycol alginate) coating composition
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
ES2322896T3 (es) * 2002-04-29 2009-07-01 Supernus Pharmaceuticals, Inc. Formulaciones farmaceuticas con biodisponibilidad mejorada.
WO2004012741A1 (en) * 2002-07-29 2004-02-12 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
US20040202755A1 (en) * 2003-04-08 2004-10-14 Myers Gale D. Speckled confection pieces
EP1633307A4 (en) 2003-06-03 2009-06-24 Isis Pharmaceuticals Inc Modulation of survivin expression
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
ATE493981T1 (de) 2003-11-04 2011-01-15 Supernus Pharmaceuticals Inc Einmal tägliche dosierformen von trospium
ES2571252T3 (es) 2004-02-06 2016-05-24 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust Uso de aminosalicilatos en el síndrome de intestino irritable con predominio de diarrea
NZ554277A (en) 2004-10-20 2010-09-30 Antisense Therapeutics Ltd Antisense modulation of integrin alpha 4 expression
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
JP5495792B2 (ja) * 2007-01-05 2014-05-21 チバ ホールディング インコーポレーテッド 有機顔料とヒュームドシリカとの共粉砕
AR065877A1 (es) 2007-03-29 2009-07-08 Progenics Pharm Inc Antagonoistas del receptor opioide periferico y usos de los mismos
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
MX2009012188A (es) 2007-05-11 2010-02-24 Univ Jefferson Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
BRPI0810336A2 (pt) * 2007-05-11 2019-03-19 The Trustees Of The University Of Pennsylvania "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
CN101896170A (zh) * 2007-11-13 2010-11-24 赫尔克里士公司 用于营养品和药物剂型的水分散性肠溶衣配制物
ES2709633T3 (es) * 2007-12-21 2019-04-17 Dr Willmar Schwabe Gmbh & Co Kg Uso de un extracto de hojas de Ginkgo biloba
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
US20100034959A1 (en) * 2008-08-07 2010-02-11 Vector Corporation High solids, high molecular weight polymer coating
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
CA2857546A1 (en) 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CA2908096C (en) 2013-03-27 2022-05-03 Isarna Therapeutics Gmbh Modified tgf-beta oligonucleotides
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
EP3211081A1 (en) 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Novel approach for treating inflammatory disorders
US10647987B2 (en) 2016-02-26 2020-05-12 Secama Pharmaceuticals GmbH & Co KG Approach for treating inflammatory disorders
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN110191952A (zh) 2016-10-07 2019-08-30 瑟卡尔纳制药有限公司 治疗癌症的新方法
EP4520828A3 (en) 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
AU2020269886A1 (en) 2019-05-03 2021-12-02 Secarna Pharmaceuticals Gmbh & Co. Kg PD-L1 antisense oligonucleotides for use in tumor treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2455790A (en) * 1945-06-09 1948-12-07 Eastman Kodak Co Enteric coatings
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
US2897122A (en) * 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3449489A (en) * 1965-10-21 1969-06-10 William E Gaunt Pharmaceutical compositions and their preparation
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
DE2612889B1 (de) * 1976-03-26 1977-09-01 Basf Ag UEberzugsmittel fuer Arzneiformlinge
DE2966893D1 (en) * 1978-10-02 1984-05-17 Purdue Research Foundation Foods and pharmaceutical coating composition, method of preparation and products so coated
BE886416A (fr) * 1979-11-29 1981-03-16 Colorcon Composition de revetement comestible seche formant une pelicule, son procede de preparation et produits revetus de ladite composition
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form

Also Published As

Publication number Publication date
EP0156852A1 (en) 1985-10-09
JPH0534333B2 (enExample) 1993-05-21
WO1985001207A1 (en) 1985-03-28
KR850700009A (ko) 1985-10-21
JPS60502207A (ja) 1985-12-19
AU3397184A (en) 1985-04-11
US4556552A (en) 1985-12-03
PH21092A (en) 1987-07-16

Similar Documents

Publication Publication Date Title
IT8448873A0 (it) Composizione per rivestimento enterico di compresse farmaceutiche esimili
IS1307B6 (is) Aðferð til að framleiða lyfjablöndu
PT86974A (pt) Process for the preparation of imidazol compounds and of biociddal compositions containing the same
KR880005932A (ko) 신경중독손상을 감소시키기 위한 약제 조성물
KR890701101A (ko) 제약학적 조성물
IT1173707B (it) Procedimento per la produzione di una composizione di rivestimento per pavimenti
IT1162879B (it) Composizioni farmaceutiche
PT87470A (pt) Process for the preparation of novel substituted benzamides and of pharmaceutical compositions containing the same
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
DK165355C (da) Fremgangsmaade til mikroindkapsling af laegemidler
IT1209615B (it) Composizione farmaceutica
PT87024A (pt) Process for the preparation of propiolophenone derivatives and of pharmaceutical compositions containing the same
PT88682A (pt) A process for the preparation of pharmaceutical compositions containing a piperidinoalkanol-decongestant combination
DE3269306D1 (en) Pharmaceutical compositions for treating nail infections
FR2527078B1 (fr) Compositions pharmaceutiques anti-ulceres
PT76734B (en) Process for preparing therapeutically active dihydropyridines of intermediates for the process and of pharmaceutical compositions containing the same
AU561447B2 (en) Pharmaceutical composition of cyproheptadine
MX11584A (es) Composiciones farmaceuticas
IT7949403A0 (it) Imminotiazolil ureido cefalosporine composizioni farmaceutiche che le contengono e procedimento per la loro preparazione
DE3460934D1 (en) Pharmaceutical composition of glafenine
IT1199948B (it) Composizioni farmaceutiche comprendenti la bromocriptina
GB2026471B (en) Dihydropyridine compound processes for preparation thereof and pharmaceutical composition of the same
ZA848741B (en) Pharmaceutical composition for inhibition of tumours
FI831893L (fi) Foerfarande foer framstaellning av en farmaceutisk vattenhaltig komposition
DK68790A (da) Anvendelse af tripeptidet l-pyroglutamyl-l-histidylglycin til fremstilling af laegemidler